The loss of ELF1 through chromosomal deletion or mRNA downregulation can contribute to prostate cancer progression by allowing for increased binding of stronger ETS transactivators at cell migration genes and by decreasing ELF1's ability to activate cellular senescence or death upon treatment with chemotherapies. This evidence concerns the gene ELF1 and prostate carcinoma.